Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cytomegalovirus glycoprotein B (HCMV gB), encoded by the UL55 gene, is an essential class III viral fusion protein required for the entry of the virus into host cells (UniProt P06473). It exists as a homotrimer on the viral envelope and mediates the fusion of the viral envelope with the host cell membrane through a series of complex conformational changes (Burke & Heldwein, 2015). Domain II of the gB ectodomain is a critical structural component that contains the Antigenic Domain 2 (AD-2), a site recognized by potent, broadly neutralizing antibodies (Pötzsch et al., 2011). Because of its indispensable role in both initial infection and subsequent cell-to-cell spread, gB is a primary target for the development of vaccines and therapeutic monoclonal antibodies. Therapeutic agents targeting Domain II specifically aim to block the fusion process, thereby preventing the delivery of the viral genome into the host cell. However, the presence of extensive glycosylation and the structural complexity of the protein present significant challenges for achieving high-level, durable immunity (Cui et al., 2018).
Neutralization of viral infectivity by binding to the Antigenic Domain 2 (AD-2) of glycoprotein B to prevent the conformational transition from pre-fusion to post-fusion state, thereby inhibiting viral-cell membrane fusion.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human cytomegalovirus glycoprotein B (HCMV gB) (HCMV gB).